CAS NO: | 149709-44-4 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Sacubitrilat (Desethyl Sacubitril) is an activeneprilysin(NEP) inhibitor. | ||||||||||||||||
IC50& Target | Neprilysin[1] | ||||||||||||||||
体外研究 (In Vitro) | Sacubitrilat (LBQ657) is a single diastereomer with specific stereocenters. Sacubitrilat is bound to the active site of NEP by an intricate network of interactions that involves all functional groups of the compound giving rise to the high inhibitory potency of 5 nM[1]. | ||||||||||||||||
体内研究 (In Vivo) | Pharmacokinetics of Sacubitril, Sacubitrilat (LBQ657), and valsartan following the administration of single oral doses of LCZ696 400 or 1200 mg under fasting condition are summarized. The mean plasma concentrations of Sacubitril increases rapidly with a median Tmaxof 0.52 h for the 400 mg dose and 1.05 h for the 1200 mg dose, followed by Sacubitrilat, with the corresponding Tmaxvalues of 2.07 and 3.05 h, respectively. The median Tmaxfor valsartan is 2.07 h for both the LCZ696 400 mg and 1200 mg doses. The Cmaxof Sacubitrilat shows a dose proportional increase, while the Cmaxof Sacubitril and Valsartan shows less than proportional increases between the doses. The arithmetic mean AUC0-24 hand AUClastfor Sacubitril and Sacubitrilat increases approximately dose proportionally, but shows less than dose proportional increase for Valsartan[2]. | ||||||||||||||||
分子量 | 383.44 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C22H25NO5 | ||||||||||||||||
CAS 号 | 149709-44-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(260.80 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|